# A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

> **NCT07645287** · PHASE2 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 175 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** GS-3242 Tablet
- **DRUG:** GS-3242 Injection
- **DRUG:** Lenacapavir Tablet
- **DRUG:** Lenacapavir Injection
- **DRUG:** B/F/TAF

## Key facts

- **NCT ID:** NCT07645287
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2027-08
- **Final completion:** 2033-04
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2026-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07645287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07645287, "A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07645287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*